These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26268906)

  • 1. Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF).
    Baker JH; McPhee KC; Moosvi F; Saatchi K; Häfeli UO; Minchinton AI; Reinsberg SA
    Contrast Media Mol Imaging; 2016; 11(1):77-88. PubMed ID: 26268906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitizing oxygenation changes in murine tumors treated with VEGF-ablation therapy are measurable using oxygen enhanced-MRI (OE-MRI).
    Baker JHE; Moosvi F; Kyle AH; Püspöky Banáth J; Saatchi K; Häfeli UO; Reinsberg SA; Minchinton AI
    Radiother Oncol; 2023 Oct; 187():109795. PubMed ID: 37414252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.
    Ye Z; Zhou Z; Ayat N; Wu X; Jin E; Shi X; Lu ZR
    Contrast Media Mol Imaging; 2016; 11(1):32-40. PubMed ID: 26218648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
    Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
    Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.
    Malamas AS; Jin E; Zhang Q; Haaga J; Lu ZR
    Pharm Res; 2015 Sep; 32(9):3029-43. PubMed ID: 25840948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations.
    Raatschen HJ; Fu Y; Shames DM; Wendland MF; Brasch RC
    Invest Radiol; 2006 Dec; 41(12):860-7. PubMed ID: 17099424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice.
    Feng Y; Jeong EK; Mohs AM; Emerson L; Lu ZR
    Magn Reson Med; 2008 Dec; 60(6):1347-52. PubMed ID: 19025902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
    Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P
    Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
    Cheng HL; Wallis C; Shou Z; Farhat WA
    J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.
    Egeland TA; Simonsen TG; Gaustad JV; Gulliksrud K; Ellingsen C; Rofstad EK
    Radiat Res; 2009 Sep; 172(3):339-47. PubMed ID: 19708783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model.
    Park HS; Han JK; Lee JM; Kim YI; Woo S; Yoon JH; Choi JY; Choi BI
    Korean J Radiol; 2015; 16(5):1029-37. PubMed ID: 26357497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights.
    Hompland T; Gulliksrud K; Ellingsen C; Rofstad EK
    Acta Oncol; 2013 Apr; 52(3):627-35. PubMed ID: 23126523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent.
    Sirlin CB; Vera DR; Corbeil JA; Caballero MB; Buxton RB; Mattrey RF
    Acad Radiol; 2004 Dec; 11(12):1361-9. PubMed ID: 15596374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging of tumor necrosis.
    Egeland TA; Gaustad JV; Galappathi K; Rofstad EK
    Acta Oncol; 2011 Apr; 50(3):427-34. PubMed ID: 20950229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Quantitative Lung Perfusion Imaging Using the Dual-Bolus Approach: Comparison of 3 Contrast Agents and Recommendation of Feasible Doses.
    Veldhoen S; Oechsner M; Fischer A; Weng AM; Kunz AS; Bley TA; Köstler H; Ritter CO
    Invest Radiol; 2016 Mar; 51(3):186-93. PubMed ID: 26606550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo mapping of fractional plasma volume (fpv) and endothelial transfer coefficient (Kps) in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure.
    Marzola P; Farace P; Calderan L; Crescimanno C; Lunati E; Nicolato E; Benati D; Degrassi A; Terron A; Klapwijk J; Pesenti E; Sbarbati A; Osculati F
    Int J Cancer; 2003 Apr; 104(4):462-8. PubMed ID: 12584744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents.
    Zong Y; Wang X; Jeong EK; Parker DL; Lu ZR
    Magn Reson Imaging; 2009 May; 27(4):503-11. PubMed ID: 18814987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.